lawsuit semaglutide Novo accuses Lilly of running 'false and misleading' GLP-1 ads Lawsuits claiming Ozempic, other GLP-1s

Marygrace Taylor Author Marygrace Taylor is an award-winning freelance health and wellness writer with more than 15 years of experience covering topics including womens health, nutrition, chronic conditi...

A method for preventing drug-induced ototoxicity in an individual in need thereof comprising intratympanic administration of a pharmaceutical composition comprising a therapeutic agent selected from a JNK inhibitor, a TRPV modulator, a MET channel inhibitor, and an otoprotectant to the individual in need thereof, wherein the pharmaceutical composition is administered prior to onset of therapy with the drug, and wherein the composition provides sustained release of the therapeutic agent into the ear for a period of at least 5 days after a single administration

Comparison with healing peptides BPC-157 promotes healing through pathways that include angiogenesis and growth factor modulation

Decaffeinated green tea catechins + chlorogenic acids Included to enhance post-meal GLP-1 response and support insulin sensitivity, especially after higher-calorie meals